Overview

A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
Recurrent Respiratory Papillomatosis (RRP) causes wart-like lesions along the throat area and can obstruct the airway or become malignant. The cause has been related to specific types of Human Papillomavirus (HPV). The purpose of the study is to assess the clinical effectiveness of a trial drug, SGN-00101, in children with RRP and also assess its safety.
Phase:
Phase 2
Details
Lead Sponsor:
Nventa Biopharmaceuticals Corporation